5Xue WL,Warshawsky D. Metabolic activation of polycyclic and heterocyclic aromatic hydrocarbons and DNA damage : A review. Toxicol Applied Pharmacol,2005,206 ( 1 ) : 73 -93.
6Diaz R, Nguewa PA, Parrondo R, et al. Aesneatrciht uartm or and antiangiogenic effect of the dual EGFR and HER - 2 tyrosine kinase inhibitor lapatinib in a lung cancer model. BMC Cancer,2010,10:158.
7Agarwal S, Zerillo C, Kolmakova J, et al. Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non - small - cell lung cancer cells. British Journal of Cancer,2009,100 : 941 - 949.
8DiGiovanna MP,Stern DF,Edgerton SM,et al. Relationship of epidermal growth factor receptor expression to ErbB - 2 signaling activity and prognosis in breast cancer patients. J Clin Oncol, 2005,23 : 1152 - 1160.
9Hirsch FR, Scagliotti GV, Langer C J, et al. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer,2003,41 ( Suppl 1 ) : S29 - S42.
10Marmor M D ,Skaria K B ,Yarden Y. Singal transduction and oncogen- esis by ErbB/HER receptors. Int J Radiat Oneol Biol Phys,2004,58 (3) :903 -913.
